MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1197.74%
Quick Ratio
1197.74%
Cash Ratio
990.94%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Less accumulated amortization
    • Deferred offering costs
    • Prepaid expenses and other curre...
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable and accrued exp...
    • Common stock, par value 0.001, 1...
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
2,626
3,675
4,491
5,575
Vendor advances, gross
1,756
1,756
3,271
3,271
Less accumulated amortization
1,344
1,131
2,426
2,214
Vendor advances, net
412
625
845
1,057
Prepaid expenses and other current assets
136
143
51
24
Total current assets
3,174
4,443
5,387
6,656
Deferred offering costs
1,282
1,279
1,091
1,308
Intangible assets, net
-
22
62
102
Total other assets
1,282
1,301
1,153
1,410
Total assets
4,456
5,744
6,540
8,066
Accounts payable and accrued expenses
265
431
199
402
Total current liabilities
265
431
199
402
Common stock, par value 0.001, 100,000,000 shares authorized 21,423,300 and 20,821,353 shares issued and outstanding on june 30, 2026 and december 31, 2025, respectively
21
21
21
21
Additional paid-in capital
21,474
21,208
20,582
20,540
Accumulated deficit
-17,304
-15,916
-14,262
-12,897
Total shareholders equity
4,191
5,313
6,341
7,664
Total liabilities and shareholders equity
4,456
5,744
6,540
8,066
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Vendor advances, gross$1,756K (-46.32%↓ Y/Y)Cash and cashequivalents$2,626K (-13.45%↓ Y/Y)Vendor advances, net$412K (-76.00%↓ Y/Y)Prepaid expenses andother current assets$136K (54.55%↑ Y/Y)Deferred offering costs$1,282K (-24.23%↓ Y/Y)Less accumulatedamortization$1,344K (-13.51%↓ Y/Y)Total current assets$3,174K (-34.41%↓ Y/Y)Total other assets$1,282K (-30.10%↓ Y/Y)Total assets$4,456K (-33.22%↓ Y/Y)Total liabilities andshareholders equity$4,456K (-33.22%↓ Y/Y)Total shareholdersequity$4,191K (-30.12%↓ Y/Y)Total currentliabilities$265K (-60.80%↓ Y/Y)Accumulated deficit-$17,304K (-50.48%↓ Y/Y)Additional paid-in capital$21,474K (22.86%↑ Y/Y)Accounts payable andaccrued expenses$265K (-60.80%↓ Y/Y)Common stock, par value0.001, 100,000,000...$21K (16.67%↑ Y/Y)

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)